Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: The role of CYP2B6 genetic variation

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Pinillos, Francoise ^a   Dandara, Collet ^b   Swart, Marelize ^b   Strehlau, Renate ^a   Kuhn, Louise ^c   Patel, Faeezah ^a   Coovadia, Ashraf ^a   Abrams, Elaine ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Vagelos College of Physicians and Surgeons   (United States)

^d Surgeons Columbia University ^*  (United States)

Author keywords

Antiretroviral treatment; Cerebellum; CNS; CYP2B6; Efavirenz; HIV; Paediatric HIV; Paediatrics; Seizures

Indexed keywords

ABACAVIR; CYTOCHROME P450 2B6; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; TETRYZOLINE; VALPROIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYP2B6 PROTEIN, HUMAN;

ABSENCE; ALLERGIC CONJUNCTIVITIS; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILD BEHAVIOR; CHILD HEALTH CARE; COMPUTER ASSISTED TOMOGRAPHY; CYP2B6 GENE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLASGOW COMA SCALE; HETEROZYGOTE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR PUNCTURE; MALE; NEUROIMAGING; NEUROLOGIC EXAMINATION; PERINATAL INFECTION; PRESCHOOL CHILD; PSYCHOLOGIC ASSESSMENT; SCHOOL CHILD; SOUTH AFRICAN; TIME TO TREATMENT; TONIC CLONIC SEIZURE; ZIMBABWEAN; BLOOD; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; GENETICS; HAPLOTYPE; HIV INFECTIONS; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTI-HIV AGENTS; BENZOXAZINES; CENTRAL NERVOUS SYSTEM; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2B6; FEMALE; HAPLOTYPES; HIV INFECTIONS; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84956818202     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1381-x     Document Type: Article

References (47)

1. Coovadia A, Abrams E, Strehlau R, Shiau S, Pinillos F, Martens L, et al. Virologic efficacy of efavirenz maintanance therapy in neviripine prophylaxis-exposed children. Boston: 21st CROI; 2014.
2. National Department of Health. Guidelines for the management of HIV in children. 2nd ed. South Africa: National Department of Health; 2010.
3. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1):71-5.
4. Kuhn L, Coovadia A, Strehlau R, Martens L, Hu CC, Meyers T, et al. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012;12(7):521-30.
5. Strehlau R, Martens L, Coovadia A, Dandara C, Norman J, Maisel J, et al. Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J. 2011;30(11):1001-3.
6. National Department of Health. National antiretroviral treatment guidelines. South Africa: National Department of Health; 2004.
7. National Department of Health. The South African antiretroviral treatment guidelines. South Africa: National Department of Health; 2013.
8. National Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. South Africa: National Department of Health; 2015.
9. Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Thery F, Shaffer N, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27(9):1403-12.
10. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143(10):714-21.
11. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009;10(6):343-55.
12. Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr. 2015;69(4):422-9.
13. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. AIDS Rev. 2010;12(2):67-75.
14. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011;15(8):1803-18.
15. Read TR, Carey D, Mallon P, Mijch A, Goodall R, Hudson F, et al. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS. 2009;23(16):2222-3.
16. Teglas JP, Quartier P, Treluyer JM, Burgard M, Gregoire V, Blanche S. Tolerance of efavirenz in children. AIDS. 2001;15(2):241-3.
17. McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the first pediatric switch study. Pediatrics. 2003;111(3):e275-81.
18. Lowenhaupt EA, Matson K, Qureishi B, Saitoh A, Pugatch D. Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis. 2007;45(10):e128-30.
19. Wintergerst U, Hoffmann F, Jansson A, Notheis G, Huss K, Kurowski M, et al. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother. 2008;61(6):1336-9.
20. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics. 2009;19(4):300-9.
21. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287-300.
22. Cabrera SE, Santos D, Valverde MP, Dominguez-Gil A, Gonzalez F, Luna G, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother. 2009;53(7):2791-8.
23. Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, la Porte CJ. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther Drug Monit. 2013;35(1):78-83.
24. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther. 2008;325(1):284-92.
25. Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics. 2012;22(12):858-67.
26. Nolan D, Phillips E, Mallal S. Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin Infect Dis. 2006;42(3):408-10.
27. Saitoh A, Fletcher CV, Brundage R, Alvero C, Fenton T, Hsia K, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. J Acquir Immune Defic Syndr. 2007;45(3):280-5.
28. ter Heine R, Scherpbier HJ, Crommentuyn KM, Bekker V, Beijnen JH, Kuijpers TW, et al. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther. 2008;13(6):779-87.
29. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18(18):2391-400.
30. Lee SS, To KW, Lee MP, Wong NS, Chan DP, Li PC, et al. Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms. Int J STD AIDS. 2014;25(3):193-200.
31. Martin AS, Gomez AI, Garcia-Berrocal B, Figueroa SC, Sanchez MC, Calvo Hernandez MV, et al. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics. Pharmacogenomics. 2014;15(7):997-1006.
32. Powers V, Ward J, Gompels M. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation. HIV Med. 2009;10(8):520-3.
33. Bienvenu E, Swart M, Dandara C, Ashton M. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. Antiviral Res. 2014;102:44-53.
34. Mehlotra RK, Bockarie MJ, Zimmerman PA. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol. 2007;64(3):391-5.
35. Sarfo FS, Zhang Y, Egan D, Tetteh LA, Phillips R, Bedu-Addo G, et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother. 2014;69(2):491-9.
36. Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics. 2013;23(8):415-27.
37. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008;61(4):914-8.
38. Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, Shin SG, et al. Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab Dispos. 2004;32(12):1341-4.
39. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, et al. High prevalence of the CYP2B6 516G- > T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64(4):357-65.
40. Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol. 2006;62(4):267-75.
41. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics. 2005;15(12):861-73.
42. Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, et al. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother. 2014;69(8):2175-82.
43. Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis. 2009;199(6):872-80.
44. Leger P, Dillingham R, Beauharnais CA, Kashuba AD, Rezk NL, Fitzgerald DW, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis. 2009;200(6):955-64.
45. Hoody DW, Fletcher CV. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Semin Pediatr Infect Dis. 2003;14(4):286-94.
46. Puls R, Amin J, Losso M, Phanuphak P, Nwizu C, Orrell C, et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014;383(9927):1474-82.
47. Mukonzo JK, Owen JS, Ogwal-Okeng J, Kuteesa RB, Nanzigu S, Sewankambo N, et al. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS One. 2014;9(1):e86919.